About Isera Biological Limited
Data last updated:
Isera Biological Limited is a public limited company based in Pune, Maharashtra, India, recognised as a startup by DPIIT. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 13 July 2016 and has been in existence for over 10 years.
The company is registered with the Registrar of Companies (ROC), Pune, under CIN U85300PN2016PLC165483. Its GSTIN is 27AAECI2033E1Z1 (Maharashtra).
The company has an authorised share capital of ₹19 Cr and a paid-up capital of ₹16.18 Cr. It was formerly known as Isera Biological Private Limited. It is led by directors including Pratap Dadasaheb Deshmukh (Managing Director) and Vinayak Bhaskarrao Shinde.
Its last annual general meeting (AGM) was held on 31 December 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at Flat – 504 Bldg – A S No – 671/2A/3 Navkar Residency Bh – Chowky Bibwewadi, Pune, Maharashtra, India – 411037.
As per the financials filed for FY 2025, the company reported a revenue of ₹18.94 Cr, a growth of 83% compared to the previous year. For the same year it recorded a net profit of ₹5.22 Cr (net margin 27.6%) and EBITDA of ₹8.25 Cr (EBITDA margin 43.6%). Revenue has grown at a compounded annual rate (CAGR) of 54% over three years and 82% over five years.
The company has about 30 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: iSERA Biological. As per MCA filings, the company has open charges of ₹11.5 Cr and satisfied charges of ₹11.71 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website iserabio.com.
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social Media
- Registered AddressFlat – 504 Bldg – A S No – 671/2A/3 Navkar Residency Bh – Chowky Bibwewadi, Pune, Maharashtra, India – 411037
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Isera Biological Limited
The main business activity of Isera Biological is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Isera Biological Limited FY 2024 filings available
Isera Biological Limited reported revenue of ₹18.94 Cr (up 83% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Isera Biological Limited
Revenue has grown at a compounded annual rate (CAGR) of 82% over five years, including 83% growth in the latest year. EBITDA rose 89% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Isera Biological Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹8.25 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹5.22 Cr | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Isera Biological Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 43.6% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 27.6% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Isera Biological are in the company report.
Financial statements from FY 2017
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Isera Biological Limited
Isera Biological Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| I G Pharma Limited | ₹18.98 Cr (FY 2025) | •••• | •••• | 7.0% | •••• | Roorkee, Uttarakhand, India |
| Vanguard Therapeutics Private Limited | ₹18.98 Cr (FY 2025) | •••• | •••• | -19.0% | •••• | Telangana, India |
| Tablets Medopharm Private Limited | ₹18.97 Cr (FY 2025) | •••• | •••• | 63.0% | •••• | Chennai, Tamil Nadu, India |
| TVB Healthcare Private Limited | ₹18.97 Cr (FY 2025) | •••• | •••• | 89.0% | •••• | Delhi, India |
| Vasudha Life Science Private Limited | ₹18.95 Cr (FY 2025) | •••• | •••• | 27.0% | •••• | Brahmavara, Karnataka, India |
| Isera Biological Limited this company | ₹18.94 Cr (FY 2025) | •••• | •••• | 83.0% | •••• | Pune, Maharashtra, India |
| Kee Pharma Limited | ₹18.89 Cr (FY 2025) | •••• | •••• | 3.0% | •••• | New Delhi, Delhi, India |
| Santiago Life Sciences Private Limited | ₹18.88 Cr (FY 2024) | •••• | •••• | 5.0% | •••• | Jabalpur, Madhya Pradesh, India |
| Bayberry Pharmaceuticals Private Limited | ₹18.82 Cr (FY 2025) | •••• | •••• | 301.0% | •••• | Pune, Maharashtra, India |
| Sunwin Healthcare Private Limited | ₹18.79 Cr (FY 2025) | •••• | •••• | 47.0% | •••• | Panchkula, Haryana, India |
| Indu Drugs Private Limited | ₹18.78 Cr (FY 2025) | •••• | •••• | -10.0% | •••• | Hyderabad, Telangana, India |
Peers are the five companies nearest above and the five nearest below Isera Biological by revenue in the Pharma industry (Formulations), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Board of Directors of Isera Biological Limited
Isera Biological has 5 current directors and 6 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sumeet Dhanraj Garad | Additional Director | 13 Mar 2025 | 1 Years 6 Months | Current |
| Vinayak Bhaskarrao Shinde | Director | 20 Mar 2020 | 6 Years 6 Months | Current |
| Pratap Dadasaheb Deshmukh | Managing Director | 13 Jul 2016 | 10 Years 2 Months | Current |
| Nandkumar Subhash Kadam Also directs: Isera Lifesciences Limited | Director | 13 Jul 2016 | 10 Years 2 Months | Current |
| Dhairyasheel Vasantrao Yadav Also directs: Isera Lifesciences Limited, Advya Digital LLP | Director | 13 Jul 2016 | 10 Years 2 Months | Current |
Charges & Borrowings of Isera Biological Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Aug 2024 | Others | ₹11.5 Cr | Open |
| 07 Apr 2018 | State Bank of India | ₹11.71 Cr | Satisfied |
Total charge records: 2 View all charges
MSME Payment Delays by Isera Biological Limited
Isera Biological Limited has 2 MSME Form 1 returns on record between 2020 and 2023, listing 2 overdue payments to 1 micro and small supplier. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (1 of 1)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | •••• | •••• | •••• |
Full MSME payment history
Every supplier, amount and due date from all 2 MSME Form 1 returns is in the company report.
- Every reported supplier due
- Amounts and due dates
- Reasons given in each return
- Period-by-period history
Verified entity values are shown only after access is granted.
Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.
Associated Brands with Isera Biological Limited
Isera Biological operates one associated brand: iSERA Biological. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Development and manufacturing of lifesaving biopharmaceutical products and research services in India. | iserabio.com |
Employees and EPFO Compliance at Isera Biological Limited
Employment history and EPFO contributions of people linked to Isera Biological.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
CIN History of Isera Biological Limited
Isera Biological has one previous CIN (Corporate Identification Number): U85300PN2016PTC165483. The current CIN is U85300PN2016PLC165483, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U85300PN2016PLC165483 | Current |
| U85300PN2016PTC165483 | Previous |
Recent Activity on Isera Biological Limited
Isera Biological Limited has 11 board changes on record since 2016: 5 appointments and 6 cessations. The latest: Sumeet Dhanraj Garad was appointed as Additional Director on 13 Mar 2025.
7 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Isera Biological Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Isera Biological Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Isera Biological Limited
Isera Biological has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAECI2033E1Z1 | Maharashtra | Active | 27 Jul 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Isera Biological Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Isera Biological Limited
Isera Biological is an active public limited company based in Pune, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 13 July 2016 (10+ years old) and is registered under CIN U85300PN2016PLC165483.
Isera Biological reported revenue of ₹18.94 Cr for FY 2025 (up 83% YoY).
Isera Biological has 5 current directors:
- Pratap Dadasaheb Deshmukh - Managing Director
- Sumeet Dhanraj Garad - Additional Director
- Vinayak Bhaskarrao Shinde - Director
- Nandkumar Subhash Kadam - Director
- Dhairyasheel Vasantrao Yadav - Director
Isera Biological reported a net profit of ₹5.22 Cr (net margin 27.6%) and EBITDA of ₹8.25 Cr (EBITDA margin 43.6%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Isera Biological is 54% over three years and 82% over five years. In the latest year (FY 2025) revenue rose 83%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Isera Biological is 27AAECI2033E1Z1, registered in Maharashtra.
The CIN (Corporate Identification Number) of Isera Biological is U85300PN2016PLC165483. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Isera Biological was incorporated on 13 July 2016, making it 10+ years old. It is registered with the Registrar of Companies, Pune.
The peers of Isera Biological by revenue are I G Pharma Limited, Vanguard Therapeutics Private Limited, Tablets Medopharm Private Limited, TVB Healthcare Private Limited, Vasudha Life Science Private Limited and 5 more, all in the Pharma industry (Formulations).
Sumeet Dhanraj Garad was appointed as Additional Director on 13 Mar 2025. Mangina Rao Srinivas ceased to be Additional Director on 30 Dec 2024. Pratap Dadasaheb Deshmukh ceased to be Director on 01 Apr 2021. Isera Biological has 11 board changes on record in total.
Yes, Isera Biological is recognised as a startup by the Department for Promotion of Industry and Internal Trade (DPIIT).
Isera Biological has 2 MSME Form 1 returns on record between 2020 and 2023, listing 2 overdue payments to 1 micro and small supplier. The latest return was filed on 30 Apr 2024.